News Release
Journal Article Cites HemoVoid™in Proteomic Study of JAK mutation and cardiovascular risk
MONMOUTHJUNCTION, NJ, May24, 2022-- Biotech Support Group reports on a research article describing thesimplicity and efficiency of their hemoglobin depletion technologyfor enriching red cell proteins, in order to assess the proteomicdifferences associated with a JAK mutation relative to normalcontrols.
Thecitation is:
Liu,Wenli, et al. "Erythroidlineage Jak2 V617F expression promotes atherosclerosis througherythrophagocytosis and macrophage ferroptosis." TheJournal of Clinical Investigation (2022).
TheJAK2V617F (Jak2VF) mutation increases cardiovascular risk inmyeloproliferative disorders and in clonal hematopoiesis. Toinvestigate whether selective erythroid Jak2VF expression promotesatherosclerosis, the investigators developed hyperlipidemicErythropoietin Receptor Cre mice that express Jak2VF in the erythroidlineage (VFEpoR mice). To explore underlying defects promotingoxidative changes in Jak2VF Red Blood Cells (RBC), unbiasedproteomics profiling was conducted. The article states “…haemoglobinremoval and on-bead digestion, …was based on the protocol inHemoVoid kit. … Samples were first digested with LysC in HVWB (fromkit) with protease: protein ratio 1:100 overnight at 37 °C and thenwith trypsin in HVWB (from kit) with protease: protein ratio 1:30.”The proteomic data showed a prominent increase in EIF2AK1 (also knownas heme-regulated inhibitor, HRI) and EIF2A (Left), consistent withincreased oxidative stress. Also, there were decreased levels ofthree key enzymes in glutathione metabolism in VFEpoR RBC. Theauthors conclude that Erythroid lineage Jak2VF expression leads toqualitative and quantitative defects in RBCs that exacerbateatherosclerosis.
“Iam pleased to see that our methods for Hemoglobin removal using ourproduct HemoVoid™, red cell proteome enrichment, and on-beaddigestion were all used in this study. Through the use of twodifferent digestion enzymes, LysC and Trypsin, adapted to ourBead-assisted Sample Prep (BASP™) protocol, several proteins wereidentified by LC-MS that were differentially expressed. This articleillustrates how our products can streamline the workflow for red cellproteomics analyzed by LC-MS, in order to discover potential newbiomarkers and a better understanding of JAK mutations in disease.”,states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Formore information on HemoVoid™, visit:
http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm
Formore information on HemoVoid™LC-MS On-Bead For RBC Proteomics, visit:
https://www.biotechsupportgroup.com/HemoVoid-LC-MS-On-Bead-For-RBC-Proteomics-p/hvb.htm
Formore information of all of our Hemoglobin removal products, visit:
https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for expanding proteomic analysis.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area. For this market, keyproducts include: AlbuVoid™ and AlbuSorb™ PLUS foralbumin & IgG depletion, Cleanascite™for lipid adsorption, and HemogloBind™ and HemoVoid™ forhemoglobin removal. From these innovations, the company has acquiredknowledgebase and biomarker intellectual property assets that supportdiscoveries of protein markers from blood, with special emphasis onearly detection and personalized medical decisions for cancerpatients. For more information, go tohttp://www.biotechsupportgroup.com
Forbusiness development contact: Matthew Kuruc
732-274-2866[email protected]